Vorinostat Completed Phase 1 Trials for Recurrent Childhood Visual Pathway Glioma / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Childhood Burkitt Lymphoma / Childhood Central Nervous System Yolk Sac Tumor / Recurrent Childhood Medulloblastoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Central Nervous System Choriocarcinoma / Childhood Craniopharyngioma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Recurrent Childhood Visual Pathway and Hypothalamic Glioma / Unspecified Childhood Solid Tumor, Protocol Specific / Childhood Mixed Glioma / Childhood Meningioma / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Central Nervous System Embryonal Tumor / Childhood Central Nervous System Mixed Germ Cell Tumor / Recurrent Childhood Cerebral Astrocytoma / Childhood Central Nervous System Germinoma / Recurrent Childhood Brain Stem Glioma / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Childhood Choroid Plexus Tumor / Childhood Medulloepithelioma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Childhood Oligodendroglioma / Recurrent Childhood Ependymoma / Childhood Central Nervous System Teratoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Childhood Diffuse Large Cell Lymphoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Large Cell Lymphoma / Childhood Central Nervous System Germ Cell Tumor / Recurrent Childhood Lymphoblastic Lymphoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00994500Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma